Infertility
Conditions
Brief summary
To evaluate safety and efficacy of 3-day cetrotide therapy started on day of oocyte retrieval (Day-0) in women at high-risk for development of ovarian hyperstimulation syndrome (OHSS) after gonadotropin- releasing hormon agonist induction protocol. Patients & Methods: Forty-eight women fulfilling inclusion criteria underwent ultrasound scanning for maximal ovarian diameter (MOD) estimation and ascites grading. Patients underwent embryo freezing, but study group received 3-day Cetrotide sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8
Detailed description
The current study is conducted at Assisted Reproduction Unit at Almana general Hospital, kingdom of saudi arabia.and other private centers in Egypt. The study protocol was approved by the Local Ethical Committee. The study aimed to include women suspected to be at high risk for development of OHSS during agonist ovarian stimulation protocol.The study includes only women of couples singed written consent to participate in the study, to undergo embryo freezing and to postpone for transfer of cryopreserved embryo. All patients are clinically evaluated for the presence of abdominal pain and if present will be graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain. Patients are evaluated for the presence of nausea and/or vomiting and sense of abdominal distension. Symptoms are scored using verbal analogue scale as nil, mild, moderate, and severe symptom. Blood samples are obtained under complete aseptic condition for estimation of serum E2 level and determination of hematocrit value (Ht%) and total leucocytic count (TLC). Then, all patients underwent ultrasound scanning for estimation of ovarian measurements that were represented as the maximal ovarian diameter (MOD) and for ascites grading if present. Ultrasound scanning is performed using a 5 megahertz vaginal probe , otherwise a 3.5 megahertz, 2.6 megahertz or 5megahertz abdominal probe is used if visualization using a vaginal probe is compromised. Ascites is graded according to the quantity of fluid accumulation in the peritoneal cavity with the patient in the anti-Trendelenburg position. Women fulfilling inclusion criteria were randomely allocated,using sealed envelops, into two equal groups. Group with embryo freezing alone (Control group) or while the other group additionally receives cetrotide subcutaneous injection in a daily dose of 0.25 mg started on day of oocyte retrieval for 3 days (Study group). Symptomatic treatment for associated symptoms as analgesics, antiemetics and antispasmodics are also prescribed. Patients are categorized according to classification grading of OHSS. Class Clinical features Biochemical features Mild - Abdominal distension/ discomfort * Mild nausea/vomiting * Diarrhea * Ovarian size usually \< 8 cm No clinically important laboratory findings Moderate - Mild features plus * US evidence of ascites - Elevated Ht (\>41%) * Elevated TLC \>15,000/ ml * Hypoproteinemia Severe - Mild & Moderate features plus * Clinically detected ascites * Severe abdominal pain * Intractable nausea * Rapid weight gain (\>1 kg/24 hr) * Pleural effusion * Severe dyspnea * Oliguria/anuria * Low blood/central venous pressures * Syncope * Venous thrombosis * Hemoconcentration (Ht \>55%) * TLC \>25,000/ ml * Serum creatinine \>1.6 mg/dl * creatinine clearance \<50 ml/min * Hyponatremia (Na+\<135milliequivalent per litre) * Hypokalemia (K+ \< 5 milliequivalent per litre) * Elevated liver enzymes Critical - Severe features plus * Anuria/ Acute renal failure * Arrhythmia * Pericardial effusion * Massive hydrothorax * Thrombo-embolism * Arterial thrombosis * (ARDS)Adult respiratory distress syndrome * Sepsis - Worsening of biochemical findings seen with severe OHSS US: Ultrasound; Ht%:Ht; Hematocrit value; TLC: Total leucocytic count: ARDS; adult respiratory distress syndrome. All patients are managed as outpatients unless management of severe symptoms necessitated hospital admission. Pain scores, serum E2 levels and MOD are evaluated daily. Patients are evaluated for associated symptoms previously determined during clinical evaluation, ascites grading and TLC and Ht value were evaluated at 3 and 6 days and on end of the trial on the 8th day after oocyte retrieval.
Interventions
study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
Sponsors
Study design
Eligibility
Inclusion criteria
1. number of retrieved oocytes was ≥20 2. mean number of follicles with a diameter of \>16 mm was ≥18 3. serum E2 concentrations of ≥3500 pg/ml 4. ovarian diameter on the day of ovum retrieval of \>10 cm 5. presentation of evident symptoms of OHSS on the day of aspiration .
Exclusion criteria
1- Absence of one or more of the items of the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Daily Maximal Ovarian Diameter | 8 days | MOD (maximal ovarian diameter in mm) were evaluated daily. |
| Daily Serum E2 Levels | 8 days | Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Daily Hematocrits Value | 0-8 days. | Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%) |
| Daily Total Leucocytic Count | 0 -8days. | TLC(x 1ooo cells/ml) |
| Ultrasound Detected Severity Grades of Ascites From Days 0-8 | 0-8 days | -US detected severity grades of ascites determined at Day -0, Day -3 and Day -8. |
| Daily Numerical Pain Visual Analogue Scale Score | 8 days. | -All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain . |
Other
| Measure | Time frame | Description |
|---|---|---|
| Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | 0-6 days | -severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6. |
Countries
Egypt
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cetrotide study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8. | 24 |
| no Cetrotide control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8. | 24 |
| Total | 48 |
Baseline characteristics
| Characteristic | Cetrotide | no Cetrotide | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 24 Participants | 24 Participants | 48 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 24 Participants | 24 Participants | 48 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Egypt | 12 participants | 12 participants | 24 participants |
| Region of Enrollment Saudi Arabia | 12 participants | 12 participants | 24 participants |
| Sex: Female, Male Female | 24 Participants | 24 Participants | 48 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 24 | 0 / 24 |
| other Total, other adverse events | 0 / 24 | 0 / 24 |
| serious Total, serious adverse events | 0 / 24 | 0 / 24 |
Outcome results
Daily Maximal Ovarian Diameter
MOD (maximal ovarian diameter in mm) were evaluated daily.
Time frame: 8 days
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cetrotide | Daily Maximal Ovarian Diameter | Day-1 | 9.3 mm | Standard Deviation 4.6 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-5 | 7.8 mm | Standard Deviation 4 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-3 | 8.7 mm | Standard Deviation 4.3 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-6 | 7.5 mm | Standard Deviation 4.2 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-2 | 9.1 mm | Standard Deviation 4.2 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-7 | 7.3 mm | Standard Deviation 4 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-4 | 8.5 mm | Standard Deviation 4.3 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-8 | 7.1 mm | Standard Deviation 3.7 |
| Cetrotide | Daily Maximal Ovarian Diameter | Day-0 | 9.4 mm | Standard Deviation 4.5 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-8 | 7.9 mm | Standard Deviation 4.2 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-0 | 10.4 mm | Standard Deviation 5.8 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-1 | 10.2 mm | Standard Deviation 5.6 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-2 | 9.6 mm | Standard Deviation 4.6 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-3 | 9.4 mm | Standard Deviation 4.9 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-4 | 9.2 mm | Standard Deviation 4.7 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-5 | 9 mm | Standard Deviation 4.6 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-6 | 8.5 mm | Standard Deviation 4.6 |
| no Cetrotide | Daily Maximal Ovarian Diameter | Day-7 | 8.2 mm | Standard Deviation 4.5 |
Daily Serum E2 Levels
Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily.
Time frame: 8 days
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cetrotide | Daily Serum E2 Levels | Day-6 | 1173 picograms/ml | Standard Deviation 180 |
| Cetrotide | Daily Serum E2 Levels | Day-2 | 2772 picograms/ml | Standard Deviation 1456 |
| Cetrotide | Daily Serum E2 Levels | Day-8 | 902 picograms/ml | Standard Deviation 66 |
| Cetrotide | Daily Serum E2 Levels | Day-3 | 2067 picograms/ml | Standard Deviation 900 |
| Cetrotide | Daily Serum E2 Levels | Day-0 | 4761 picograms/ml | Standard Deviation 940 |
| Cetrotide | Daily Serum E2 Levels | Day-4 | 1452 picograms/ml | Standard Deviation 617 |
| Cetrotide | Daily Serum E2 Levels | Day-7 | 969 picograms/ml | Standard Deviation 118 |
| Cetrotide | Daily Serum E2 Levels | Day-5 | 1173 picograms/ml | Standard Deviation 180 |
| Cetrotide | Daily Serum E2 Levels | Day-1 | 3397 picograms/ml | Standard Deviation 1361 |
| no Cetrotide | Daily Serum E2 Levels | Day-5 | 1914 picograms/ml | Standard Deviation 965 |
| no Cetrotide | Daily Serum E2 Levels | Day-6 | 1544 picograms/ml | Standard Deviation 812 |
| no Cetrotide | Daily Serum E2 Levels | Day-7 | 1275 picograms/ml | Standard Deviation 588 |
| no Cetrotide | Daily Serum E2 Levels | Day-0 | 5004 picograms/ml | Standard Deviation 792 |
| no Cetrotide | Daily Serum E2 Levels | Day-1 | 4212 picograms/ml | Standard Deviation 950 |
| no Cetrotide | Daily Serum E2 Levels | Day-2 | 3620 picograms/ml | Standard Deviation 1037 |
| no Cetrotide | Daily Serum E2 Levels | Day-3 | 3592 picograms/ml | Standard Deviation 862 |
| no Cetrotide | Daily Serum E2 Levels | Day-4 | 2570 picograms/ml | Standard Deviation 914 |
| no Cetrotide | Daily Serum E2 Levels | Day-8 | 1044 picograms/ml | Standard Deviation 200 |
Daily Hematocrits Value
Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%)
Time frame: 0-8 days.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cetrotide | Daily Hematocrits Value | Day-0 | 42.2 percentge | Standard Deviation 5.2 |
| Cetrotide | Daily Hematocrits Value | Day-3 | 38.7 percentge | Standard Deviation 3.3 |
| Cetrotide | Daily Hematocrits Value | Day-6 | 37.3 percentge | Standard Deviation 2.5 |
| Cetrotide | Daily Hematocrits Value | Day-8 | 36.8 percentge | Standard Deviation 2.6 |
| no Cetrotide | Daily Hematocrits Value | Day-8 | 37.5 percentge | Standard Deviation 1.5 |
| no Cetrotide | Daily Hematocrits Value | Day-0 | 39.8 percentge | Standard Deviation 4.2 |
| no Cetrotide | Daily Hematocrits Value | Day-6 | 38 percentge | Standard Deviation 3.1 |
| no Cetrotide | Daily Hematocrits Value | Day-3 | 38.8 percentge | Standard Deviation 3.3 |
Daily Numerical Pain Visual Analogue Scale Score
-All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain .
Time frame: 8 days.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-5 | 0.92 units on a scale | Standard Deviation 1.1 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-6 | 0.33 units on a scale | Standard Deviation 0.6 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-0 | 5.3 units on a scale | Standard Deviation 1.6 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-1 | 4.3 units on a scale | Standard Deviation 1.3 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-2 | 3.6 units on a scale | Standard Deviation 1 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-3 | 2.3 units on a scale | Standard Deviation 1.8 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-4 | 1.6 units on a scale | Standard Deviation 1.2 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-7 | 0.17 units on a scale | Standard Deviation 0.38 |
| Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-8 | 0.13 units on a scale | Standard Deviation 0.34 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-8 | 1.1 units on a scale | Standard Deviation 1.7 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-5 | 3.7 units on a scale | Standard Deviation 2 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-3 | 4.6 units on a scale | Standard Deviation 1.8 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-7 | 1.6 units on a scale | Standard Deviation 1.1 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-0 | 5.4 units on a scale | Standard Deviation 1.7 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-4 | 4.5 units on a scale | Standard Deviation 1.4 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-1 | 5 units on a scale | Standard Deviation 1.3 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-6 | 2.4 units on a scale | Standard Deviation 1.1 |
| no Cetrotide | Daily Numerical Pain Visual Analogue Scale Score | Day-2 | 4.9 units on a scale | Standard Deviation 1.8 |
Daily Total Leucocytic Count
TLC(x 1ooo cells/ml)
Time frame: 0 -8days.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cetrotide | Daily Total Leucocytic Count | Day-0 | 12.75 1000 cells/ml | Standard Deviation 3.1 |
| Cetrotide | Daily Total Leucocytic Count | Day-3 | 11.5 1000 cells/ml | Standard Deviation 2.8 |
| Cetrotide | Daily Total Leucocytic Count | Day-6 | 11 1000 cells/ml | Standard Deviation 1.9 |
| Cetrotide | Daily Total Leucocytic Count | Day-8 | 9.75 1000 cells/ml | Standard Deviation 3.1 |
| no Cetrotide | Daily Total Leucocytic Count | Day-8 | 10.1 1000 cells/ml | Standard Deviation 2.2 |
| no Cetrotide | Daily Total Leucocytic Count | Day-0 | 11.6 1000 cells/ml | Standard Deviation 3.7 |
| no Cetrotide | Daily Total Leucocytic Count | Day-6 | 11.2 1000 cells/ml | Standard Deviation 3.6 |
| no Cetrotide | Daily Total Leucocytic Count | Day-3 | 11.3 1000 cells/ml | Standard Deviation 3.6 |
Ultrasound Detected Severity Grades of Ascites From Days 0-8
-US detected severity grades of ascites determined at Day -0, Day -3 and Day -8.
Time frame: 0-8 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | Low grade ascitis at Day-8 | 21 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | Low grade ascitis at Day-0 | 8 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | moderate grade ascitis at Day-0 | 16 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | severe grade ascitis at Day-3 | 0 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | moderate grade ascitis at Day-3 | 6 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | Low grade ascitis at Day-3 | 18 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | moderate grade ascitis at Day-8 | 3 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | severe grade ascitis at Day-8 | 0 US detected ascitis |
| Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | severe grade ascitis at Day-0 | 0 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | severe grade ascitis at Day-8 | 2 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | severe grade ascitis at Day-0 | 0 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | severe grade ascitis at Day-3 | 3 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | Low grade ascitis at Day-0 | 6 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | Low grade ascitis at Day-3 | 13 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | Low grade ascitis at Day-8 | 17 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | moderate grade ascitis at Day-0 | 18 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | moderate grade ascitis at Day-3 | 8 US detected ascitis |
| no Cetrotide | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | moderate grade ascitis at Day-8 | 5 US detected ascitis |
Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy
-severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6.
Time frame: 0-6 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Vomiting at Day-3 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Nausea at Day-3 | 4 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Vomiting at Day-3 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Nausea at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Vomiting at Day-6 | 24 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Nausea at Day-0 | 8 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Vomiting at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Nausea at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderat Vomiting at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Nausea at Day-3 | 1 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Vomiting at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Vomiting at Day-0 | 14 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Abdominal distension at Day-0 | 5 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Nausea at Day-0 | 5 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Abdominal distension at Day-0 | 8 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Vomiting at Day-0 | 7 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Abdominal distension at Day-0 | 9 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Nausea at Day-3 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Abdominal distension at Day-0 | 2 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderatel Vomiting at Day-0 | 2 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Abdominal distension at Day-3 | 15 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Nausea at Day-0 | 7 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Abdominal distension at Day-3 | 8 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Vomiting at Day-0 | 1 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Abdominal distension at Day-3 | 1 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Nausea at Day-6 | 24 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Abdominal distension at Day-3 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Vomiting at Day-3 | 24 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Abdominal distension at Day-6 | 24 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Nausea at Day-3 | 19 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Abdominal distension at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Vomiting at Day-3 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Abdominal distension at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Nausea at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Abdominal distension at Day-6 | 0 GI manifestations |
| Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Nausea at Day-0 | 4 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Abdominal distension at Day-6 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Nausea at Day-0 | 5 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Nausea at Day-3 | 12 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Nausea at Day-0 | 6 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Nausea at Day-0 | 7 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Nausea at Day-0 | 6 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Nausea at Day-3 | 8 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Nausea at Day-3 | 4 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Nausea at Day-3 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Nausea at Day-6 | 22 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Nausea at Day-6 | 2 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Nausea at Day-6 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Nausea at Day-6 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Vomiting at Day-0 | 12 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Vomiting at Day-0 | 8 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderatel Vomiting at Day-0 | 4 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Vomiting at Day-0 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Vomiting at Day-3 | 20 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Vomiting at Day-3 | 4 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Vomiting at Day-3 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Vomiting at Day-3 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Vomiting at Day-6 | 24 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Vomiting at Day-6 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderat Vomiting at Day-6 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Vomiting at Day-6 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Abdominal distension at Day-0 | 4 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Abdominal distension at Day-0 | 7 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Abdominal distension at Day-0 | 10 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Abdominal distension at Day-0 | 3 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Abdominal distension at Day-3 | 9 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Abdominal distension at Day-3 | 12 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Abdominal distension at Day-3 | 3 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | severe Abdominal distension at Day-3 | 0 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | Nil Abdominal distension at Day-6 | 20 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | mild Abdominal distension at Day-6 | 4 GI manifestations |
| no Cetrotide | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | moderate Abdominal distension at Day-6 | 0 GI manifestations |